Company performance
Add to research
Current Price
as of Feb 07, 2025$18.55
P/E Ratio
24.01
Market Cap
$3.09B
Description
Add to research
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Metrics
Add to research
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerACAD
- Price$18.55-3.03%
Trading Information
- Market cap$3.09B
- Float98.74%
- Average Daily Volume (1m)1,635,860
- Average Daily Volume (3m)2,409,549
- EPS$0.78
Company
- Revenue$929.24M
- Rev growth (1yr)18.28%
- Net income$32.77M
- Gross margin92.47%
- EBITDA margin13.66%
- EBITDA$34.21M
- EV$2.04B
- EV/Revenue2.20
- P/E24.01
- P/S3.32
- P/B5.35
- Debt/Equity8.55
Documents
Add to research
SEC Filings
Factset Street Account
Earnings Calls
Factset